Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ligustilide to preparation of drug for preventing and treating osteoporosis

A technology for osteoporosis and ligustilide, which is applied in the application field of ligustilide in the preparation of medicines for preventing and treating osteoporosis, and achieves the effect of improving bone formation ability

Inactive Publication Date: 2019-03-22
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report about ligustilide preventing and treating osteoporosis in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ligustilide to preparation of drug for preventing and treating osteoporosis
  • Application of ligustilide to preparation of drug for preventing and treating osteoporosis
  • Application of ligustilide to preparation of drug for preventing and treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Effects of ligustilide on prednisolone-induced zebrafish osteoporosis

[0028] Experimental animals: zebrafish AB strain was purchased from Kaiji Biotechnology Co., Ltd.; circadian rhythm: day:night=14h:10h; temperature: (28.5±0.5)°C.

[0029] Reagents and drugs: prednisolone was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; etidronate disodium was purchased from Shanghai Yuanye Biotechnology Co., Ltd.

[0030] Instrument: Leica M205FA stereo fluorescence microscope, etc.

[0031] Grouping and administration: divided into control group (0.2% DMSO), model group model (25 μM prednisolone), positive drug group DE (15 μg / ml etidronate disodium), ligustilide group LIG (0.1, 1 and 10 μM)

[0032] Experimental method: Beginning at 3 days post fertilization (dpf), zebrafish larvae were treated with 25 μM prednisolone for 6 consecutive days. Two days after modeling, etidronate disodium (DE; 15 μg / ml) was used as a positive drug, or ligustilide (0.1, 1 and 10 μM) was...

Embodiment 2

[0036] Effects of Ligustilide on Osteoblast Differentiation

[0037] Cells: The pre-osteoblast cell line MC3T3-E1 was purchased from the Cell Bank of the Shanghai Academy of Chinese Sciences, and bone marrow mesenchymal stem cells (BMSCs) derived from rat femurs were self-extracted.

[0038] Reagents and medicines: β-glycerophosphate was purchased from Sigma; dexamethasone was purchased from Sigma; ascorbic acid was purchased from Sigma.

[0039] Instrument: Leica stereo microscope, etc.

[0040] Grouping and administration: divided into blank group (0.1%DMSO), ligustilide group (10, 50 and 100 μM)

[0041] Experimental method: use α-MEM culture medium containing 10% heat-inactivated FBS, and add double antibodies to the culture medium at a dilution ratio of 1:100, at 37°C, 5% CO 2 , cultured in a saturated humidity incubator. Medium was changed every two days. When the cells grow to about 90%, trypsinize the cells into a centrifuge tube. Centrifuge at 1000 rpm for 3 min....

Embodiment 3

[0044] Effects of ligustilide on the survival rate of MC3T3-E1 cells under oxidative stress

[0045] Cells: Pre-osteogenic cell line MC3T3-E1 was purchased from the Cell Bank of Shanghai Academy of Chinese Sciences.

[0046] Instrument: Bio-Tek microplate reader.

[0047] Grouping and administration: divided into blank control group control (0.1% DMSO), model group model (0.4 mM H 2 o 2 ), ligustilide group LIG (1, 10, 50, 100 μM).

[0048] Experimental method: use α-MEM culture medium containing 10% heat-inactivated FBS, and add double antibodies to the culture medium at a dilution ratio of 1:100, at 37°C, 5% CO 2 , cultured in a saturated humidity incubator. Medium was changed every two days. When the cells grow to about 90%, trypsinize the cells into a centrifuge tube. Centrifuge at 1000 rpm for 3 min. After centrifugation, the cells were resuspended in α-MEM culture medium and counted, with 200 μl of culture medium per well, 1×10 4 Each well was seeded in a 96-well...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of ligustilide to preparation of a drug for preventing and treating osteoporosis. Ligustilide can significantly improve the zebrafish osteoporosis caused by prednisolone and significantly promote osteoblast differentiation, and increases the survival rate of osteoblasts under oxidative stress, inhibits apoptosis and then plays a protecting role for the osteoblasts. To be specific, the ligustilide can finally achieve the purpose of treating the osteoporosis by improving the bone formation capacity.

Description

technical field [0001] The invention belongs to the technical field of prevention and treatment of osteoporosis, and in particular relates to the application of ligustilide in the preparation of medicines for the prevention and treatment of osteoporosis. Background technique [0002] Osteoporosis (Osteoporosis, OP) is a common and frequently-occurring disease, which not only causes a lot of economic losses to people, but also seriously reduces the quality of life of middle-aged and elderly people, and endangers the health of middle-aged and elderly people. The most notable features of OP are decreased bone mineral density (BMD) and bone mineral content (BMC), severe loss of intraosseous trabeculae, and severe degeneration of bone microstructure. People with OP have increased bone fragility and are therefore prone to fractures. The normal operation of bone remodeling can ensure the relatively stable level of bone metabolism in the body. Bone remodeling includes bone formatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P19/10
CPCA61K31/365A61P19/10
Inventor 华永庆杨菲林紫薇洪敏宿树兰段金廒
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com